Literature DB >> 25934391

Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor Mimetics.

Ping Zhang1, Andrew J Leger1, James D Baleja1, Rajashree Rana1, Tiffany Corlin1, Nga Nguyen1, Georgios Koukos1, Andrew Bohm1, Lidija Covic1, Athan Kuliopulos2.   

Abstract

G protein-coupled receptors (GPCRs) are remarkably versatile signaling systems that are activated by a large number of different agonists on the outside of the cell. However, the inside surface of the receptors that couple to G proteins has not yet been effectively modulated for activity or treatment of diseases. Pepducins are cell-penetrating lipopeptides that have enabled chemical and physical access to the intracellular face of GPCRs. The structure of a third intracellular (i3) loop agonist, pepducin, based on protease-activated receptor-1 (PAR1) was solved by NMR and found to closely resemble the i3 loop structure predicted for the intact receptor in the on-state. Mechanistic studies revealed that the pepducin directly interacts with the intracellular H8 helix region of PAR1 and allosterically activates the receptor through the adjacent (D/N)PXXYYY motif through a dimer-like mechanism. The i3 pepducin enhances PAR1/Gα subunit interactions and induces a conformational change in fluorescently labeled PAR1 in a very similar manner to that induced by thrombin. As pepducins can potentially be made to target any GPCR, these data provide insight into the identification of allosteric modulators to this major drug target class.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  G protein-coupled receptor (GPCR); biotechnology; cell surface receptor; cell-penetrating peptide (CPP); chemical biology; drug delivery system; nuclear magnetic resonance (NMR); receptor structure-function; signal transduction; thrombin

Mesh:

Substances:

Year:  2015        PMID: 25934391      PMCID: PMC4505487          DOI: 10.1074/jbc.M115.636316

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.

Authors:  A Kuliopulos; L Covic; S K Seeley; P J Sheridan; J Helin; C E Costello
Journal:  Biochemistry       Date:  1999-04-06       Impact factor: 3.162

2.  Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding.

Authors:  Stacy Seeley; Lidija Covic; Suzanne L Jacques; James Sudmeier; James D Baleja; Athan Kuliopulos
Journal:  Chem Biol       Date:  2003-11

3.  Design and characterization of helical peptides that inhibit the E6 protein of papillomavirus.

Authors:  Yuqi Liu; Zhiguo Liu; Elliot Androphy; Jason Chen; James D Baleja
Journal:  Biochemistry       Date:  2004-06-15       Impact factor: 3.162

4.  The 2.0 A crystal structure of a heterotrimeric G protein.

Authors:  D G Lambright; J Sondek; A Bohm; N P Skiba; H E Hamm; P B Sigler
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

5.  Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation.

Authors:  Athan Kuliopulos; Ramon Mohanlal; Lidija Covic
Journal:  Thromb Haemost       Date:  2004-12       Impact factor: 5.249

6.  PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.

Authors:  Adrienne Boire; Lidija Covic; Anika Agarwal; Suzanne Jacques; Sheida Sherifi; Athan Kuliopulos
Journal:  Cell       Date:  2005-02-11       Impact factor: 41.582

7.  Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.

Authors:  Eric Yang; Adrienne Boire; Anika Agarwal; Nga Nguyen; Katie O'Callaghan; Powen Tu; Athan Kuliopulos; Lidija Covic
Journal:  Cancer Res       Date:  2009-07-21       Impact factor: 12.701

8.  Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation.

Authors:  Lidija Covic; Meghna Misra; Jehangir Badar; Christopher Singh; Athan Kuliopulos
Journal:  Nat Med       Date:  2002-09-23       Impact factor: 53.440

9.  Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis.

Authors:  Athan Kuliopulos; Lidija Covic
Journal:  Life Sci       Date:  2003-12-05       Impact factor: 5.037

10.  Evidence that helix 8 of rhodopsin acts as a membrane-dependent conformational switch.

Authors:  A Gopala Krishna; Santosh T Menon; Tracy J Terry; Thomas P Sakmar
Journal:  Biochemistry       Date:  2002-07-02       Impact factor: 3.162

View more
  13 in total

1.  Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.

Authors:  Paul A Gurbel; Kevin P Bliden; Susan E Turner; Udaya S Tantry; Martin G Gesheff; Travis P Barr; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01       Impact factor: 8.311

Review 2.  Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors.

Authors:  Madhu Chaturvedi; Justin Schilling; Alexandre Beautrait; Michel Bouvier; Jeffrey L Benovic; Arun K Shukla
Journal:  Trends Biochem Sci       Date:  2018-05-04       Impact factor: 13.807

Review 3.  Neutrophil Signaling That Challenges Dogmata of G Protein-Coupled Receptor Regulated Functions.

Authors:  Claes Dahlgren; André Holdfeldt; Simon Lind; Jonas Mårtensson; Michael Gabl; Lena Björkman; Martina Sundqvist; Huamei Forsman
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-11

4.  The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability.

Authors:  Disha M Gandhi; Ricardo Rosas; Eric Greve; Kaitlin Kentala; N'Guessan D-R Diby; Vladyslava A Snyder; Allison Stephans; Teresa H W Yeung; Saravanan Subramaniam; Elliot DiMilo; Khia E Kurtenbach; Leggy A Arnold; Hartmut Weiler; Chris Dockendorff
Journal:  Bioorg Med Chem       Date:  2019-06-29       Impact factor: 3.641

Review 5.  Targeting PAR1: Now What?

Authors:  Robert Flaumenhaft; Karen De Ceunynck
Journal:  Trends Pharmacol Sci       Date:  2017-05-27       Impact factor: 14.819

6.  Pepducin ICL1-9-Mediated β2-Adrenergic Receptor-Dependent Cardiomyocyte Contractility Occurs in a Gi Protein/ROCK/PKD-Sensitive Manner.

Authors:  Ama Dedo Okyere; Jianliang Song; Viren Patwa; Rhonda L Carter; Nitya Enjamuri; Anna Maria Lucchese; Jessica Ibetti; Claudio de Lucia; Sarah M Schumacher; Walter J Koch; Joseph Y Cheung; Jeffrey L Benovic; Douglas G Tilley
Journal:  Cardiovasc Drugs Ther       Date:  2022-01-08       Impact factor: 3.947

7.  PAR2 Pepducin-Based Suppression of Inflammation and Itch in Atopic Dermatitis Models.

Authors:  Travis P Barr; Chris Garzia; Srijoy Guha; Elizabeth K Fletcher; Nga Nguyen; Adam J Wieschhaus; Lluis Ferrer; Lidija Covic; Athan Kuliopulos
Journal:  J Invest Dermatol       Date:  2018-10-01       Impact factor: 8.551

8.  Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin.

Authors:  Andrew M Shearer; Rajashree Rana; Karyn Austin; James D Baleja; Nga Nguyen; Andrew Bohm; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2016-09-09       Impact factor: 5.157

Review 9.  New paradigms in GPCR drug discovery.

Authors:  Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2015-08-08       Impact factor: 5.858

Review 10.  Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach.

Authors:  Lidija Covic; Athan Kuliopulos
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.